Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease

D. Hadjiyiannakis; D. Dimitroyannis; L. Eastlake; C. Peedell; L. Tripathi; R. Simcock; A. Vyas; E. Deutsch; A. J. Chalmers

doi:10.1016/j.clon.2020.08.003

Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease

D. Hadjiyiannakis, D. Dimitroyannis, L. Eastlake, C. Peedell, L. Tripathi, R. Simcock, A. Vyas, E. Deutsch, A. J. Chalmers

Résultats de recherche: Contribution à un journal › Editorial

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	e64-e68
journal	Clinical Oncology
Volume	33
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.clon.2020.08.003
état	Publié - 1 janv. 2021

Accès au document

10.1016/j.clon.2020.08.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7a5f3e1ee1fa4c3bb305640526e290e9,

title = "Personal View: Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease",

author = "D. Hadjiyiannakis and D. Dimitroyannis and L. Eastlake and C. Peedell and L. Tripathi and R. Simcock and A. Vyas and E. Deutsch and Chalmers, {A. J.}",

note = "Funding Information: C. Peedell reports personal fees from Elekta, personal fees from Boston Scientific, personal fees from AstraZeneca, outside the submitted work. R. Simcock reports grants and personal fees from Novartis, personal fees from Exact Sciences, outside the submitted work. E. Deutsch reports grants and personal fees from Roche Genentech, grants from Servier, grants from AstraZeneca, grants and personal fees from Merck Serono, grants from BMS, grants from MS, outside the submitted work.The research was supported by the NIHR Lancashire Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, the Department of Health, or the Lancashire Clinical Research Facility. Funding Information: The research was supported by the NIHR Lancashire Clinical Research Facility . The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, the Department of Health, or the Lancashire Clinical Research Facility. Funding Information: C. Peedell reports personal fees from Elekta , personal fees from Boston Scientific , personal fees from AstraZeneca , outside the submitted work. R. Simcock reports grants and personal fees from Novartis , personal fees from Exact Sciences , outside the submitted work. E. Deutsch reports grants and personal fees from Roche Genentech , grants from Servier , grants from AstraZeneca , grants and personal fees from Merck Serono , grants from BMS , grants from MS, outside the submitted work. ",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/j.clon.2020.08.003",

language = "English",

volume = "33",

pages = "e64--e68",

journal = "Clinical Oncology",

issn = "0936-6555",

number = "1",

}

TY - JOUR

T1 - Personal View

T2 - Low-Dose Lung Radiotherapy Should be Evaluated as a Treatment for Severe COVID-19 Lung Disease

AU - Hadjiyiannakis, D.

AU - Dimitroyannis, D.

AU - Eastlake, L.

AU - Peedell, C.

AU - Tripathi, L.

AU - Simcock, R.

AU - Vyas, A.

AU - Deutsch, E.

AU - Chalmers, A. J.

N1 - Funding Information: C. Peedell reports personal fees from Elekta, personal fees from Boston Scientific, personal fees from AstraZeneca, outside the submitted work. R. Simcock reports grants and personal fees from Novartis, personal fees from Exact Sciences, outside the submitted work. E. Deutsch reports grants and personal fees from Roche Genentech, grants from Servier, grants from AstraZeneca, grants and personal fees from Merck Serono, grants from BMS, grants from MS, outside the submitted work.The research was supported by the NIHR Lancashire Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, the Department of Health, or the Lancashire Clinical Research Facility. Funding Information: The research was supported by the NIHR Lancashire Clinical Research Facility . The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, the Department of Health, or the Lancashire Clinical Research Facility. Funding Information: C. Peedell reports personal fees from Elekta , personal fees from Boston Scientific , personal fees from AstraZeneca , outside the submitted work. R. Simcock reports grants and personal fees from Novartis , personal fees from Exact Sciences , outside the submitted work. E. Deutsch reports grants and personal fees from Roche Genentech , grants from Servier , grants from AstraZeneca , grants and personal fees from Merck Serono , grants from BMS , grants from MS, outside the submitted work.

PY - 2021/1/1

Y1 - 2021/1/1

UR - http://www.scopus.com/inward/record.url?scp=85089584724&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2020.08.003

DO - 10.1016/j.clon.2020.08.003

M3 - Editorial

C2 - 32829986

AN - SCOPUS:85089584724

SN - 0936-6555

VL - 33

SP - e64-e68

JO - Clinical Oncology

JF - Clinical Oncology

IS - 1

ER -